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oriented risk assessment using concrete patient circum-
stances. The indication for the use of antiseptics results from 
the addition of differently weighted risk causes, for which 
points are assigned. Antimicrobial treatment is justified in 
the case of 3 or more points.  Copyright © 2011 S. Karger AG, Basel 
 Introduction and Problem 
 To date, there is no generally accepted definition for 
risk wounds, synonymously referred to as wounds at risk 
(W.A.R.) or wounds at risk of infection.
 Because of the lack of a clear definition, many wounds 
are classified as being ‘potentially at risk of infection’. 
Therefore, the excessive use – in terms of frequency and 
duration – of topical, antiseptically efficacious products 
is often the expression of a non-evidence-based empirical 
safety consciousness. On the other hand, it is important 
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 Abstract 
 Currently, there are no generally accepted definitions for 
wounds at risk of infection. In clinical practice, too many 
chronic wounds are regarded as being at risk of infection, 
and therefore many topical antimicrobials – in terms of fre-
quency and duration of use – are applied to wounds. Based 
on expert discussion and current knowledge, a clinical as-
sessment score was developed. The objective of this wounds 
at risk (W.A.R.) score is to allow decision-making on the indi-
cation for the use of antiseptics on the basis of polihexanide. 
The proposed clinical classification of W.A.R. shall facilitate 
the decision for wound antisepsis and allow an appropriate 
general treatment regimen with the focus on the prevention 
of wound infection. The W.A.R. score is based on a clinically 
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to identify at-risk patient groups or critical wound condi-
tions in order to prevent serious infections, by consisten-
cy in wound management practices.
 Objective 
 The expert recommendation presented here aims at 
contributing to the clarification of the term ‘risk wound’ 
and to provide an aid in the decision process as to which 
situations justify the use of antiseptics as a therapeu-
tic measure for preventing wound infections. Since evi-
dence-based guidelines regarding this topic are mostly 
missing, this recommendation reflects the consensus of 
an interdisciplinary and interprofessional expert group 
in the assessment of the current medical state of know-
ledge and their own clinical experience  [1] .
 Polihexanide was selected as an antiseptic reference 
substance because of its favourable benefits and risks in 
wound care, which is supported by considerable evidence 
 [2–4] .
 Factors Relating to Risk Assessment 
 Not only the existing pathogen burden and the type(s) 
of pathogens are of importance, but also their virulence 
and the interactions with the patient’s resistance. These 
all play an important role in assessing the question of the 
probability of development of a wound infection.
 The following general infectiological equation clari-
fies the correlation: 
infection risk
number of pathogens pathogenicity of the pathogens
 immune system
? ?
patient’s
 (adapted from Archibald and Hierholzer  [1] ). 
 This means for example: the greater the denominator, 
i.e. the better the patient’s state of immune competence, 
the lower the probability of infection. On the other hand, 
by reduction of the numerator, particularly by reduction 
of the number of pathogens, the risk of infection can also 
be reduced.
 Pathogen Burden 
 The microbiological evidence of the presence of mi-
cro-organisms on a wound, healing by secondary inten-
tion, is not automatically equivalent to an infection. De-
pending on the pathogen count, the proliferation behav-
iour, and the immunological response of the host, the 
following microbial wound situations are differentiated:
 •  contamination, i.e. micro-organisms are present and 
have attached to the tissue (microbial attachment), 
without (initial) proliferation; 
 •  colonization, i.e. micro-organisms are present and are 
proliferating; a clinically significant immunological 
host reaction is (initially) absent; 
 •  critical colonization, i.e. significant microbial prolif-
eration without the formation of classical signs of in-
fection but delayed wound healing due to toxin pro-
duction, for example; 
 •  local infection, i.e. clinically observable, immunological 
host reaction with the typical signs of infection includ-
ing redness (erythema  1 2 cm measured from the wound 
margin with tendencies of increase could be equivalent 
to spreading infection with the risk of generalization) 
 [5] , swelling, increased local skin/tissue temperature, 
pain, functional impairment, and increase in exudate 
quantity and viscosity, for example, perceptible odour 
and stagnation in wound healing  [5, 6] ; 
 •  generalized infection, i.e. in addition to the local in-
flammatory reactions, signs of a systemic host reac-
tion such as leucocytosis, increase in C-reactive pro-
tein and fever may be observed  [7] . 
 The purely quantitative consideration of the microbial 
load of a wound (e.g. a guide value of  1 10 5 pathogens per 
gram of tissue) cannot be implemented as standard in 
clinical routine and is not sufficient to be able to assess 
the degree of the infection risk in wounds in general. Ac-
companied by a poor immune response of the patient 
and/or a special pathogenicity of the pathogen, wound 
contamination with virulent pathogens can already rep-
resent a risk for the patient despite a low pathogen load. 
A typical example is colonization with methicillin-resis-
tant  Staphylococcus aureus (MRSA).
 The concept of ‘critical colonization’ continues to be 
controversially discussed, because it cannot be accurately 
defined from a microbiological or from a clinical point of 
view but is widely used in practice  [6] . Here, too, the two 
factors of pathogen virulence and immune competence 
of the patient are coresponsible for whether or not a colo-
nized wound develops into a critically colonized or an 
infected wound. Accordingly, in the course of wound 
healing the occurrence of the aforementioned clinical 
signs and symptoms of wound infection must be care-
fully heeded. Local and/or systemic antimicrobial mea-
sures must be taken, if necessary.
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 Microbiological Evidence and Pathogenicity of the 
Pathogen 
 Regardless of the pathogen-harvesting technique 
(qualitatively using surface swabs, semiquantitatively us-
ing an expanded surface swab examination or quantita-
tively using a rinsing technique or tissue biopsy), current 
microbiological standard diagnostics for wound investi-
gation are characterized by a number of drawbacks. Es-
sentially, the following factors limit the value of micro-
biological standard diagnostics in the context of wound 
treatment  [8] :
 • the recovery rate of pathogens from the wound; 
 • the effectiveness of sampling types, e.g. swab versus 
biopsy; 
 • the only limited predictive value on relevance of the 
potentially demonstrated pathogens; 
 • the time required for the preparation of the microbio-
logical findings; 
 • the chronicity of the wound; 
 • the localization (e.g. depth) of bacteria. 
 Reproduction of the results with respect to the repro-
ducibility rate of the micro-organisms is frequently un-
satisfactory. It is generally a local material removal that 
insufficiently includes the deeper parts of the floor of the 
wound. Moreover, the pathogens responsible for main-
taining impaired wound healing or wound infection may 
be protected under a biofilm which can elude identifica-
tion  [8] .
 Even in the event of one or several species of micro-
organisms being present, the predictive value of stan-
dard microbiological sampling is limited with respect to 
clinical relevance. As a rule, the standard findings pro-
vide only information on genus (class) and species (type) 
of the micro-organisms, if necessary, as well as their sen-
sitivity to selected antibiotics. Information on the pres-
ence or absence of specific pathogenicity factors is not 
provided. The pathogenicity of a microbial strain de-
pends on the virulence factors that a particular micro-
bial strain produces. Accordingly, relevant virulence 
factors such as the production of the enzymes coagu - 
lase, metalloproteinases or staphyloxanthin, a carot-
enoid pigment that has both cytotoxic and anti-oxida-
tive effects, are – in terms of maintaining a wound in-
fection – more probable in  S. aureus isolates than for 
example in  Staphylococcus epidermidis isolates, but they 
are also strain dependent within a species. The ‘classical’ 
microbiological finding does not distinguish between 
pathogens and less pathogenic strains of a species. The 
only statement on virulence can be taken from the anal-
ysis of sensitivity to antibiotics. However, this analysis is 
only of indirect relevance, because the possible antibi-
otic resistance is relevant only when systemic antibiotic 
treatment is necessary. However, in the event of second-
ary sepsis resulting from a wound infection, knowledge 
of antibiotic sensitivity is often crucial for the patient’s 
prognosis  [9, 10] .
 Another limitation results from the required time of 
2–5 days for growth of bacterial cultures following sam-
pling (point of clinically identified risk) and availability 
of a microbiological result. A deterioration of the patient’s 
condition up to the manifestation of infection can al-
ready have occurred in this interval  [7, 9, 10] .
 In principle, easy-to-use ‘rapid tests’ are available, but 
these tests are highly specific for selected pathogens and 
have been insufficiently studied in practical application. 
Currently, there is a need for action as early as the time of 
identification of the clinical problem. The results of the 
microbiological diagnostics can then later either confirm 
or reject this decision. In the event of a transition to a sys-
temic infection, the microbiological findings admittedly 
facilitate the selection of necessary options for systemic 
therapy (e.g. the selection of the appropriate antibiotic) 
and provide, with respect to epidemiological consider-
ations, information on the locally expected spectrum of 
pathogens  [7, 9, 11, 12] .
 One aspect of the microbiological findings focusing 
on the pathogen, including its antibiotic resistance profile 
which should be considered separately, relates to the de-
tection of multiresistant bacteria. Herein included are the 
MRSA strains, including community-acquired MRSA 
strains with a high risk of necrotizing infection, extend-
ed-spectrum   -lactamase-producing Gram-negative bac-
teria or glycopeptide-/vancomycin-resistant enterococci. 
When these pathogens are present, an antiseptic measure 
is always justified, because antibiotic-resistant bacteria – 
even if they lack strain-dependent specific virulence fac-
tors for causing a local wound infection – have prognosti-
cally less favourable effects on the affected patient in the 
event of a systemic infection, but also on neighbouring 
patients in the event of accidental transmission (cross-
contamination)  [5, 9, 10, 12–15] .
 Immunological Status of the Patient 
 Clinical experience has shown that in an otherwise 
generally healthy person, who has an isolated chronic ve-
nous leg ulcer, the ulcer can persist for years without in-
fection  [16] . A chronic wound is not necessarily to be con-
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sidered as a risk wound. On the other hand, the factors 
that impair a patient’s immune competence are frequent-
ly the same – such as poorly controlled diabetes mellitus, 
immunosuppressives, malnutrition or arterial circulato-
ry disorders – that are also responsible for delayed wound 
healing. These factors may of course contribute to chro-
nicity. The actual infection risk of patients both with 
chronic and acute wounds depends critically on their ba-
sic immunological situation. 
 Risk Wounds (W.A.R., Wounds at Risk of Infection) 
 From the clinical point of view, the causes of a particu-
lar infection risk can be divided into two groups ( fig. 1 ):
 – the  endogenous factors have an effect on the develop-
ment of a wound infection and can essentially be 
traced back to a weakening of the patient’s immune 
system; 
 – the  external (exogenous) factors weighing upon the 
wound situation are related to the quantity and patho-
genicity of the pathogen and its susceptibility to the 
antiseptic agent. 
 Wounds with Endogenous Infection Risk 
 The term ‘immunosuppression’ generally describes 
the activities in which immunological processes are sup-
pressed. In the immunosuppressed patient, complicated 
and frequently also chronic wounds occur increasingly. 
These can be subdivided into neoplasms (e.g. squamous 
cell carcinoma), infections (e.g. lues maligna), vasculiti-
des (e.g. secondary vasculitis in systemic lupus erythema-
tosus) and specific wounds (e.g. ulcer ating graft-versus-
host disease). In particular, the  bacterial superinfections 
in the course of erysipelas, a phlegmon up to the develop-
ment of sepsis, are dreaded complications and occur 
more frequently in  mmunosuppressed patients com-
pared with those who are immunocompetent.
 Fundamentally, the distinction must be made between 
congenital and acquired immune defects in patients with 
an immunological disorder.
 Congenital Immune Defects 
 Defects in antibody production constitute the major-
ity (about 50%) of all congenital immune defects. Exam-
ples of these diseases include agammaglobulinaemia, 
Wounds at parcular risk of infecon
Endogenously and immunologically
increased risk of infecon
Exogenously and non-immunologically
increased risk of infecon
• Congenital immune defects
• Acquired immune defects
• Immunosuppressive medicaon
• Diabetes mellitus
• Advanced age
• Young age (premature infants, babies,
infants)
• Burn wounds
• Malnutrion
• Heavily contaminated wounds
(gunshot, bite, traumac wounds)
• Presence of foreign bodies
• Postsurgical wounds following proce-
dures with high microbial contaminaon
• Specific pathogenicity and virulence
of the pathogen present in the wound
• Risk due to locaon (e.g. perineal surgery)
• Environmental risks (e.g. occupaonal
and lifestyle risks)
 Fig. 1. Risk factors for wound infection. 
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common variable immunodeficiency and hyper-IgM 
syndrome. Other congenital immune defects are based 
on B-cell defects such as the Bruton-Gitlin syndrome, on 
T-cell defects such as Nezelof syndrome or on combined 
B-cell and T-cell defects such as severe combined im-
munodeficiency, Wiskott-Aldrich syndrome, Di George 
syndrome or Louis-Bar syndrome.
 Acquired Immune Defects 
 The substantially more commonly occurring acquired 
immune defects can be caused, for example, by the fol-
lowing factors  [17–20] :
 • infectious diseases such as AIDS, cytomegaly or mea-
sles; 
 • neoplasms, e.g. leukaemia, lymphoma; 
 • medicines, e.g. glucocorticoids; 
 • auto-immune diseases, e.g. systemic lupus erythema-
tosus or rheumatoid arthritis; 
 • decreased cellular immune response and cellular se-
nescence; 
 • age; 
 • malnutrition; 
 • splenectomy; 
 • burns; 
 • diabetes mellitus. 
 Immunologically Relevant Medicines 
 In the case of medicines, the relevant active substance 
groups can be divided into:
 • glucocorticoids, e.g. prednisone, prednisolone or 
dexamethasone, which have a direct inhibitory effect 
on T cells and an indirect effect also on B cells; 
 • cytostatic agents, e.g. alkylating agents such as cyclo-
phosphamide or melphalan, which block cell division 
by insertion of alkyl groups into the DNA, antime-
tabolites such as methotrexate or azathioprin, which 
as purine, pyrimidine or folic acid analogues block 
both DNA and RNA synthesis, and intercalators such 
as doxorubicin or mitoxanthrone, which bind non-co-
valently to the DNA and thus block its replication; 
 • antibodies, e.g. anti-CD3 (catumaxomab), anti-CD20 
(rituximab) or anti-CD25 (basiliximab); 
 • immunosuppressive agents, by which alteration of im-
munophilins, e.g. with cyclosporine, tacrolimus or si-
rolimus, results, for example, in T-cell inhibition via 
inhibition of calcineurin. 
 Finally, there are also other immunosuppressive med-
icines of which mycophenolate mofetil, which inhibits B 
cells and T cells through the inhibition of the synthesis of 
guanosine nucleotides, is an example  [19] .
 Infection Risk in the Context of Diabetic Foot 
Syndrome, Diabetic Podopathy 
 Peripheral neuropathy with loss of important senso-
ry, motor and autonomic functions is the most impor-
tant cause of ulceration, which occurs after trauma or 
by pressure causing deformations of the feet in diabetic 
patients.
 Among the factors that can favour wound infection in 
patients who have diabetes is the deficient acid-protective 
coat of the skin caused by sebostasis and sudomotor im-
pairment, associated with cracks, fissures and skin de-
fects triggered by mycoses, which facilitate invasion by 
pathogens and a high pathogen diffusion due to absent 
sensory warning signals. Likewise, reduced arterial cir-
culation to the lower extremity can also be a significant 
factor. According to current knowledge, it is certain that 
micro-angiopathy does not result in occlusion of the ar-
terioles and capillaries. However, thickened basal mem-
branes, which cause poorer oxygen permeation into the 
tissue, is observed in the small arterioles. However, due 
to the loss of autonomic control of the arteriovenous 
shunts and loss of postural constriction, there is perma-
nent hyperperfusion. Glycated haemoglobin transports 
less oxygen in diabetic patients, and in addition, the re-
duced deformability of the erythrocytes causes poorer 
oxygen supply to the tissues. The resulting perturbed 
protein synthesis following hypoxia also results in a re-
duced local resistance to infection  [21–23] .
 The generalized reduced immune response in patients 
who have diabetes is attributed to a limited leucocyte and 
monocyte activity, with a reduction of chemotaxis and 
phagocytosis. Systemic and local immune deficits also 
account for the fact that the classical inflammatory reac-
tions like fever or leucocytosis seen in wound infections 
are absent in a large proportion of patients with diabetes 
 [22–26] .
 Infection Risk in the Context of Burns and Scalds 
 Burns and scalds are thermal damage to the skin and 
connective tissues; a burn is damage by fire or contact 
with hot objects, a scald is caused by hot liquids or steam.
 Infections are among the feared complications where-
by, in extensive burns, sepsis is the cause of a fatal out-
come in more than 50%. Approximately 1 week after a 
burn, it can be assumed that every burn wound is micro-
bially colonized or already infected. Ideal conditions for 
micro-organisms are found on burn and scald wounds. 
Due to the sustained destruction of the skin barrier, the 
reduced general immune defence and the deteriorated 
microcirculation, this risk is explainable  [17, 20, 27–29] .
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 Wounds with Exogenous Infection Risk 
 Infection Risk in Postoperative or Iatrogenic Wounds 
 Unplanned secondary wound healing, following skin 
dehiscence, in a postsurgical wound intended for prima-
ry closure, frequently results in a particular risk of micro-
bial wound healing disorders  [12, 30, 31] .
 Gunshot, Bite and Contaminated Wounds 
 Heavily Contaminated Wounds 
 Abrasions, lacerations, crush and impalement wounds 
inflicted outdoors can be heavily exogenously contami-
nated. In addition to the dermal flora, including MRSA, 
for example, primarily  Clostridium and  Bacillus spp., 
even Rabies Virus, can be introduced into the wound.
 Bite Wounds 
 A bite wound is a tissue injury that is inflicted by a per-
son or by an animal. About 60–80% of bite injuries are 
caused by dogs, 20–30% by cats. In rural areas, human 
bites are rare; in cities, they can reach up to 20% of bite 
injuries. The greatest concern in a bite wound is the trans-
mission of infectious diseases such as tetanus, hepatitis or 
rabies. Damage to tendons, muscles or nerves can also oc-
cur. While the transmission of zoonoses such as rabies, cat 
scratch disease, cat pox, rat bite fever, tularaemia, brucel-
losis or leptospirosis is rare following an animal bite, and 
tetanus has become rare following an animal bite or acci-
dental trauma, wound infections can run a serious course, 
including disseminated infection and sepsis, particularly 
when caused by oral flora. In the case of bite injuries – in 
part due to the selective diagnostic methods used – only 
few bacterial strains are isolated from the wound. Thus, in 
cat and dog bites,  Pasteurella canis, Pasteurella multocida 
or  Mannheimia haemolytica are most commonly isolated, 
whereas  S. aureus, Streptococcus pyogenes, Canocytophaga 
 canimorsus, Neisseria and  Moraxella spp. are rarer causes 
of wound infection. Anaerobic organisms can be found in 
39% of animal and in 50% of human bite wounds. Fre-
quent anaerobic organisms are  Bacteroides, Fusobacteri-
um, Peptococcus, Veillonella,  Porphyromonas and  Prevo-
tella spp. In bite wounds inflicted by humans, wound in-
fections, also including systemic infections, can be caused 
by  Eikenella corrodens,   -lactamase-resistant anaerobes, 
extended-spectrum   -lactamase-producing forms and 
MRSA. Finally, the possibility of transmission of hepatitis 
B and syphilis must be considered; it must be kept in mind 
that cat bites are associated with a higher infection rate 
than dog bites, because of the puncture-like bite wound 
and the deeper inoculation of the pathogens. Depending 
on location, the infection risk averaged  6 20% in bite in-
juries caused by human beings, and after dog bites it was 
between 3 an 17%, respectively  [32] .
 As no demonstration of a pathogen can initially be 
made, the risk of a wound infection must be minimized 
to the greatest possible extent in conjunction with the use 
of antiseptics and antibiotics.
 While primary closure of bite wounds to the face and 
head is unquestionably the method of choice, the notion 
is increasingly taking hold that also in other regions de-
layed closure should be considered only for wounds al-
ready infected and for wounds at particular risk of infec-
tion, because surgical care in conjunction with antisepsis 
determines the success of treatment to a considerable de-
gree. Better cosmetic outcomes together with quicker 
wound healing can be achieved after primary closure. 
Primary suture can be undertaken within a period of up 
to 12 h after surgical treatment, antisepsis and, if re-
quired, single-shot antibiotic prophylaxis. Even infected 
wounds can be primarily closed after installation of a 
drain  [32] .
 Gunshot Wounds 
 Gunshot wounds are a special type of acute, traumatic 
wound. They are caused by the blunt force of projectiles 
or projectile particles and are a combination of laceration 
and crush wounds. The projectile causes a direct tissue 
laceration upon entry, exit and traversing of the body re-
lated to the kinetic energy of the projectile (1/2 mv 2 ). De-
pending on the shape of the projectile, the tissue yielding 
to the sides of the projectile experiences a high radial ac-
celeration with significant heat development and tissue 
destruction (cavitation effect). Injuries with mole guns 
are particularly dangerous because contaminated soil is 
carried into the depths of the wound.
 In the case of gunshot wounds, exploration and de-
bridement of the projectile channel and the exit wound, 
and – if applicable – vessel reconstruction, bone stabiliza-
tion using an external fixator, and exploration of the ab-
dominal and thoracic cavity must be considered  [12, 14, 
33] . 
 Environmental Risks 
 Because the skin plays an essential role in infection 
defence, the wound represents a potential risk, which may 
present differently depending on external conditions 
such as occupation, personal hygiene and the location of 
the wound.
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 Occupational Risk 
 Many patients with chronic wounds are still able to 
work. In a study for the 2007 Disease Management Pro-
gram, the average age of patients with chronic wounds 
was 68 ( 8 12) years. Particularly in rurally structured liv-
ing environments, many persons work in agriculture be-
yond the retirement age. This results in hygienically dif-
ficult conditions due to the pathogen burden in the envi-
ronment, footwear and clothing. Similarly problematic 
are, for example, occupations on building sites, in auto-
motive workshops, in ports, in recycling sites and waste 
depots, or in woodworking operations. Therefore, when 
taking a history from a patient, the recording of social 
data and evaluation of the occupational environment are 
important. For example, the provision of footwear with 
safety steel toes required by the employer impairs pres-
sure relief, and pathogen proliferation in the shoes is fa-
voured by the moist and warm environment. The same 
applies to rubber boots when working in a barn  [16] .
 Lorry drivers are an occupational group that is at par-
ticular pressure risk. Due to the long periods of sitting on 
plastic seats without the opportunity to shift their weight, 
pressure points may occur in the sacral region. Many seek 
medical treatment late because they underestimate the 
problem, they are embarrassed or are afraid of losing 
their job. These skin lesions are at risk of infection due to 
the location of the wound and the unfavourable ventila-
tion situation. Pilonidal sinus is also a typical problem in 
this occupational group.
 Occupational risks must not be underestimated in 
healthcare workers either. Different facultative pathogens 
or pathogenic disease organisms are found in hospitals, 
medical practices and nursing homes. In the case of inju-
ries, this may present a particular risk (e.g. infection with 
MRSA)  [34] .
 Influence of Personal Hygiene 
 Handling dressings with inadequate hand hygiene in-
creases the risk of wound infection. Gardening, as well as 
do-it-yourself activities or cleaning, also contains a po-
tential risk. Pseudomonads and other aqueous pathogens 
can colonize water lines, showerheads and faucet aerators 
and can be transmitted when flushing wounds. Hygiene 
deficiencies can also result in cross-contamination with 
respect to foot baths  [35] .
 Risk due to Wound Location 
 Particular body regions have a higher microbial bur-
den than others  [27, 35] . This applies to the perineal re-
gion, the feet, facial wounds or abdominal wounds with 
existing anus praeter. Due to the more difficult fixation 
of dressings, hair-covered skin represents, primarily 
from the hair follicles, a risk of infiltration or migration 
by wound pathogens  [36] . This problem is also present in 
the case of wounds in the area of external fixators, probes, 
tracheal cannulas and catheters  [37] .
 Furthermore, the patient’s individual medical situa-
tion needs to be considered. Systemic antibiotic prophy-
laxis is recommended in patients with risk for endocar-
ditis, e.g. patients with known vulnerable cardiac valves, 
mechanical cardiac valves or presence of permanently 
implanted prosthetic medical devices.
 Wounds are at potential risk of infection by virtue of 
unfavourable external circumstances. Careful analysis of 
living conditions related to hygienic conditions and the 
patient’s activities is necessary, in order to determine the 
individual risk  [16, 38] .
 Risk Score: The W.A.R. Score 
 The creation of a checklist in the form of a score for 
risk wounds ( table 1 ) serves the objective of enabling a 
clinically oriented elaborate risk assessment using spe-
cific patient circumstances. The indication for use of an-
tiseptics results from the addition of differently weighted 
risk causes, for which points are assigned. Antimicrobial 
treatment is justified in the case of 3 or more points.
 This score represents a recommendation which is 
open for discussion and which was formulated due to the 
absence of evident data based on comprehensive clinical 
experience. It needs to be verified in practice and con-
tinuously adapted.
 The Role of Polihexanide in Risk Wounds 
 In view of the known actions of polihexanide and its 
positive risk-benefit evaluation, it appears to be advanta-
geous to use preparations containing polihexanide in the 
risk situations described above with the clear indications 
of the risk wound  [3, 7, 39, 40] .
 Bite injuries are an exception. In these cases, surface-
active antiseptics like octenidine, polihexanide or chlor-
hexidine could theoretically support eradication by vir-
tue of their surface tension but may not be active in the 
depth of wounds in contrast to alcohols and povidone-
iodine, which can even be systemically absorbed. The 
absence of absorption of these active substances when 
used on wounds may favour this hypothesis in contrast 
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to povidone-iodine and alcohols in this situation. Since 
the application of octenidine under pressure in stab in-
juries in the paediatric hand resulted in protracted oede-
matous adverse effects with tissue damage, pressurized 
administration into tissues is contraindicated. This 
would apply analogously to polihexanide and chlorhexi-
dine. Flushing of deep wounds (e.g. bite injuries) with 
topically active strong protein-binding antiseptics is per-
missible only if drainage of the rinsing fluid is provided 
 [11, 33, 41–45] .
 The basics of the therapeutic use of polihexanide in 
infected wounds have been defined in another expert rec-
ommendation  [7] .
 Table 2 provides an overview of the efficacy and toler-
ability of the substance.
 Justified, longer-term, even repeated, application to 
risk wounds must be clearly delimited from this. The rel-
evant risk factors are shown in  table 1 .
 Overall, therapy with antiseptic solutions or support-
ive use of antimicrobial wound dressings is reasonable if 
it is integrated in a supervised clinical course of treatment. 
Here, the frequency of a change of dressing is dependent 
on the overall wound status. Daily change of dressings is 
often required for infected wounds. For wounds at risk of 
infection (W.A.R.) this is dependent on wound status and 
can be in a range of 2–7 days. Application must generally 
Table 1.  Classification for wounds at risk: the W.A.R. score
Risk class Risk definition (based on risk status and different indications) Points (W.A.R.)
Class 1 (a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
(k)
(l)
(m)
Acquired immunosuppressive disease (e.g. diabetes mellitus)
Acquired immune defect due to medical therapy such as cyclosporine,
methotrexate, glucocorticoids or antibodies
Solid tumour disease
Systemic haematological disease
Postsurgical wound healing disorder, which results in (unplanned) secondary 
healing
Potentially heavily contaminated wounds (e.g. perineum, genitals)
Problematic hygienic conditions related to social or occupational environment 
(e.g. agriculture, lorry driving)
Patient age >80 years
Young age of patient (premature infants, babies, infants)
Wounds persisting for >1 year
Wound dimensions of >10 cm2
Chronic wounds of any aetiology having a depth of >1.5 cm
Extended inpatient status >3 weeks
The presence of each risk factor
adds 1 risk point
(multiple responses are possible)
The points are added
Class 2 (a)
(b)
(c)
Severe acquired immune defects (e.g. HIV infection)
Heavily contaminated acute wounds
Bite, stab and gunshot wounds penetrating 1.5–3.5 cm
The presence of each risk factor
adds 2 risk points
(multiple responses are possible)
The points are added
Class 3 (a)
(b)
(c)
(d)
Burn wounds with involvement of >15% BSA
Wounds that have a direct connection to organs or functional structures
(e.g. including joints) or which contain foreign material
Severe congenital immune defects such as agammaglobulinaemia,
severe combined immune defects, etc.
Bite, stab and gunshot wounds penetrating >3.5 cm
The presence of each risk factor
adds 3 risk points
(multiple responses are possible)
The points are added
Finally, the risk factor points are added to obtain a total score. A score 63 points indicates the presence of a wound clinically at 
risk of infection and consequently represents a clinical indication for the administration of local antiseptics. 
B SA = Body surface area.
Regardless of this recommendation, other treatment indications may be present, which themselves require local antimicrobial treat-
ment such as: elimination of pathogens when multiply resistant pathogens are present specified by the Robert Koch Institute; criti-
cally colonized wounds.
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be reviewed no later than 21 days. With a continuation of 
the risk (W.A.R.), the continuing therapeutic procedure 
must be decided on an individual basis  [7] .
 When there is suspicion of deep transmitted infection, 
systemic antimicrobial therapy must be inaugurated  [5, 
7, 12] .
 Use, Available Preparations and Route of 
Administration 
 In wound antisepsis, polihexanide solutions are com-
monly used at concentrations of 0.01, 0.02 and 0.04%. The 
solution should be used only for local applications, e.g. for 
rinsing (lavage), rinse/suction drainage or moist wound 
dressings. Since polihexanide has a delayed action, and 
the individual pathogens respond to the agent with dif-
ferent levels of sensitivity over time, it is important to al-
low a minimum exposure time of 10–15 min after the 
wound base has been thoroughly wetted. This is an inter-
mittent, repeated use.
 Polihexanide as an antimicrobial component in wound 
dressings or gels supplements the benefits of moist wound 
care with the increased security of a continuous eradica-
tion of wound pathogens.
 The polihexanide-containing products used in the 
context of wound care differ in their forms of administra-
tion (antiseptics, wound flushing solutions, gels, wound 
dressings) and have different properties by virtue of their 
different vehicles. They have specific indications (anti-
septic = drug) or intended uses (medical device) and must 
be evaluated differently for their clinical efficacy.
 For this, it must be ensured that the products are used 
exclusively in accordance with their stated indications or 
intended uses  [7] .
 Contraindications 
 According to the current state of knowledge, there are 
relative contraindications to the use of polihexanide:  [2, 
3, 7, 11, 48–50] :
 • for antiseptic joint lavage (cartilage toxicity); 
 • in applications involving any part of the central ner-
vous system, including the meninges, and intralum-
bal/intrathecal applications; 
 • for applications involving the middle or inner ear, or 
for intra-ocular applications; 
 • during the first 4 months of pregnancy (at any time 
thereafter, a strict benefit/risk assessment has to be 
performed); 
 • in patients allergic to polihexanide. 
 Conclusion and Summary 
 The W.A.R. score described in  table  1 is helpful for 
optimizing the risk evaluation of the wound at risk of in-
fection. Classification of these risk wounds into a general 
therapy scheme is thereby simplified.
 Because of the assignment of the different microbio-
logical statuses and the clinical situation, a simple and 
practical grading scheme is described for the therapy of 
these wounds ( fig. 2 ).
Table 2. Efficacy and tolerability of polihexanide
Efficacy Tolerability
Broad antimicrobial effect Good clinical tolerability
Very low minimum blood/protein error (limitation of
effect on mucous membranes due to presence of mucin)
Selective, specific mechanism of action
After-effect, postantiseptic effect Biocompatibility index >1 [quotient from cell toxicity (IC50)
and microbicidal efficacy (RF >lg 3 = microbial count reduction by 
more than 3 log units), tested in fetal bovine serum]
Concentration-dependent promotion of wound healing [46] No known toxic risks
Anti-inflammatory properties No known resorption risks
No known development of resistance Sustainability of the active ingredient
Reduction of biofilm and fibrin formation [47] Low risk of contact sensitization
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 This makes it possible to maintain a summarizable re-
quirement-oriented selection of methods available in the 
clinical routine, and to adequately care for every wound 
after assessment of the concrete risk situation.
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